1. Home
  2. CRBP vs VATE Comparison

CRBP vs VATE Comparison

Compare CRBP & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • VATE
  • Stock Information
  • Founded
  • CRBP 2009
  • VATE 1994
  • Country
  • CRBP United States
  • VATE United States
  • Employees
  • CRBP N/A
  • VATE N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • CRBP Health Care
  • VATE Industrials
  • Exchange
  • CRBP Nasdaq
  • VATE Nasdaq
  • Market Cap
  • CRBP 96.5M
  • VATE 98.2M
  • IPO Year
  • CRBP N/A
  • VATE 1996
  • Fundamental
  • Price
  • CRBP $8.22
  • VATE $5.65
  • Analyst Decision
  • CRBP Strong Buy
  • VATE
  • Analyst Count
  • CRBP 10
  • VATE 0
  • Target Price
  • CRBP $53.56
  • VATE N/A
  • AVG Volume (30 Days)
  • CRBP 215.8K
  • VATE 19.4K
  • Earning Date
  • CRBP 08-05-2025
  • VATE 08-06-2025
  • Dividend Yield
  • CRBP N/A
  • VATE N/A
  • EPS Growth
  • CRBP N/A
  • VATE N/A
  • EPS
  • CRBP N/A
  • VATE N/A
  • Revenue
  • CRBP N/A
  • VATE $1,066,100,000.00
  • Revenue This Year
  • CRBP N/A
  • VATE N/A
  • Revenue Next Year
  • CRBP $270.04
  • VATE N/A
  • P/E Ratio
  • CRBP N/A
  • VATE N/A
  • Revenue Growth
  • CRBP N/A
  • VATE N/A
  • 52 Week Low
  • CRBP $4.64
  • VATE $3.25
  • 52 Week High
  • CRBP $61.90
  • VATE $13.79
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 54.23
  • VATE 52.05
  • Support Level
  • CRBP $7.26
  • VATE $5.20
  • Resistance Level
  • CRBP $7.90
  • VATE $5.76
  • Average True Range (ATR)
  • CRBP 0.53
  • VATE 0.25
  • MACD
  • CRBP -0.01
  • VATE 0.08
  • Stochastic Oscillator
  • CRBP 78.59
  • VATE 84.72

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Share on Social Networks: